NO980915D0 - Rekombinante anti-CD4-antistoff egnet for human terapi - Google Patents
Rekombinante anti-CD4-antistoff egnet for human terapiInfo
- Publication number
- NO980915D0 NO980915D0 NO980915A NO980915A NO980915D0 NO 980915 D0 NO980915 D0 NO 980915D0 NO 980915 A NO980915 A NO 980915A NO 980915 A NO980915 A NO 980915A NO 980915 D0 NO980915 D0 NO 980915D0
- Authority
- NO
- Norway
- Prior art keywords
- human therapy
- recombinant anti
- antibody suitable
- antibody
- recombinant
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/523,894 US6136310A (en) | 1991-07-25 | 1995-09-06 | Recombinant anti-CD4 antibodies for human therapy |
PCT/US1996/014324 WO1997009351A1 (en) | 1995-09-06 | 1996-09-05 | Recombinant anti-cd4 antibodies for human therapy |
Publications (3)
Publication Number | Publication Date |
---|---|
NO980915D0 true NO980915D0 (no) | 1998-03-03 |
NO980915L NO980915L (no) | 1998-05-06 |
NO324497B1 NO324497B1 (no) | 2007-10-29 |
Family
ID=24086874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19980915A NO324497B1 (no) | 1995-09-06 | 1998-03-03 | Chimerisk anti-CD4-antistoff, fremgangsmate for fremstilling derav, DNA-kodende for et slikt antistoff samt anvendelse derav for fremstilling av et medikament til behandling av en ikke-autoimmun sykdom. |
Country Status (24)
Country | Link |
---|---|
US (5) | US6136310A (no) |
EP (1) | EP0854885B1 (no) |
JP (1) | JP3619866B2 (no) |
KR (1) | KR100491222B1 (no) |
CN (1) | CN100391978C (no) |
AP (1) | AP1193A (no) |
AT (1) | ATE348113T1 (no) |
AU (1) | AU717674B2 (no) |
BG (1) | BG64651B1 (no) |
BR (1) | BR9610404A (no) |
CA (1) | CA2231182A1 (no) |
CZ (1) | CZ291036B6 (no) |
DE (1) | DE69636760T2 (no) |
HK (1) | HK1016995A1 (no) |
HU (1) | HU221351B1 (no) |
IL (1) | IL123447A0 (no) |
MX (1) | MX9801732A (no) |
NO (1) | NO324497B1 (no) |
NZ (1) | NZ316835A (no) |
OA (1) | OA10671A (no) |
RO (1) | RO120198B1 (no) |
RU (1) | RU2232773C2 (no) |
SK (1) | SK27998A3 (no) |
WO (1) | WO1997009351A1 (no) |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
EP0938334A4 (en) * | 1996-07-26 | 2004-12-15 | Smithkline Beecham Corp | IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES |
GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
US6893636B2 (en) * | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7033589B1 (en) | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
WO1998058966A1 (en) * | 1997-06-24 | 1998-12-30 | Norman Godin | A composition for specific immunoprotection and method for obtaining said composition |
US7189400B2 (en) | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL209786B1 (pl) * | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2001068133A1 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
JP2003535592A (ja) * | 2000-06-06 | 2003-12-02 | アイデック ファーマスーティカルズ コーポレイション | ヒトgp39に対する非アゴニスト抗体、含有する組成物、およびその治療的使用 |
US20070065436A1 (en) * | 2001-01-31 | 2007-03-22 | Biogen Idec Inc. | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
US20020159996A1 (en) * | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US20030211107A1 (en) * | 2002-01-31 | 2003-11-13 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
AR035779A1 (es) * | 2001-02-06 | 2004-07-14 | Genetics Inst Llc | Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
GB2376466A (en) * | 2001-06-14 | 2002-12-18 | Mark Frewin | TRX1 antibody |
US7541443B2 (en) * | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
CA2452005C (en) * | 2001-07-10 | 2011-03-15 | Idec Pharmaceutical Corporation | Inhibition of apoptosis process and improvement of cell performance |
GB2380127A (en) * | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
EP1432431B1 (en) | 2001-10-04 | 2017-05-10 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 activity |
MXPA04004634A (es) | 2001-11-16 | 2004-08-12 | Idec Pharma Corp | Expresion policistronica de anticuerpos. |
EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
US20080108560A1 (en) * | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
US20040009546A1 (en) * | 2002-04-22 | 2004-01-15 | Jan Holgersson | Compositions and methods for inhibiting microbial adhesion |
US8034351B2 (en) * | 2002-04-22 | 2011-10-11 | Recopharma Ab | Mucin fusion polypeptide vaccines, compositions and methods of use thereof |
AU2003232994B2 (en) * | 2002-04-22 | 2009-07-23 | Recopharma Ab | Lewis Y epitope modified polypeptide, or mucin fusion polypeptide, tumor vaccines |
CA2491320A1 (en) | 2002-07-15 | 2004-01-22 | Wyeth | Methods and compositions for modulating t helper (th) cell development and function |
WO2004015057A2 (en) * | 2002-08-09 | 2004-02-19 | Recopharma Ab | Mucin-immunoglobulin fusion proteins |
EP1543166A4 (en) * | 2002-09-27 | 2009-10-28 | Genentech Inc | SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME |
JP4988201B2 (ja) | 2002-10-16 | 2012-08-01 | ユーロ−セルティーク エス.エイ. | 細胞結合性ca125/o772pに結合する抗体およびその使用方法 |
CN101928344B (zh) * | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
JP4033390B2 (ja) * | 2002-10-30 | 2008-01-16 | 独立行政法人科学技術振興機構 | 不死化ナチュラルキラー細胞株 |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
EP1625165A2 (en) * | 2003-04-03 | 2006-02-15 | Protein Design Labs, Inc. | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
CA2530972A1 (en) * | 2003-06-11 | 2004-12-23 | Wyeth | Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof |
GB2406094B (en) * | 2003-09-17 | 2007-06-06 | Antisoma Plc | Modified antibody comprising an amino acid substitution mutation which confers increased stability |
JP2007534305A (ja) * | 2003-11-07 | 2007-11-29 | アムジェン インコーポレイテッド | サル免疫グロブリン配列 |
JP5848861B2 (ja) * | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Cd20に対するヒトモノクローナル抗体 |
CA2574848A1 (en) * | 2004-08-05 | 2006-12-21 | Wyeth | Antagonizing interleukin-21 receptor activity |
JP2008517073A (ja) * | 2004-10-14 | 2008-05-22 | レコファーマ アーベー | Helicobacterpylori付着およびHelicobacterpylori感染を阻害するための組成物ならびに方法 |
US7589182B1 (en) | 2005-01-07 | 2009-09-15 | Los Alamos National Security, Llc | Anti-sulfotyrosine antibodies |
US20060193849A1 (en) * | 2005-02-25 | 2006-08-31 | Antisoma Plc | Biological materials and uses thereof |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
WO2007058776A2 (en) * | 2005-11-10 | 2007-05-24 | Receptor Biologix, Inc. | Hepatocyte growth factor intron fusion proteins |
JP2009514627A (ja) * | 2005-11-10 | 2009-04-09 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 再狭窄の低減 |
US7495097B2 (en) * | 2005-11-23 | 2009-02-24 | Brown University | Rhodium quinonoid catalysts |
EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
US20090181041A1 (en) * | 2006-01-23 | 2009-07-16 | Jan Holgersson | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
CA2637947A1 (en) * | 2006-01-23 | 2007-07-23 | Recopharma Ab | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
US20070184065A1 (en) | 2006-01-26 | 2007-08-09 | Jan Holgersson | Compositions and Methods for Inhibiting Viral Adhesion |
US20080279848A1 (en) * | 2006-03-16 | 2008-11-13 | Genentech, Inc. | Methods of treating lupus using CD4 antibodies |
EP2001510A4 (en) * | 2006-03-16 | 2010-06-09 | Genentech Inc | METHODS OF TREATING LUPUS USING CD4 ANTIBODIES |
TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
EP2362224A3 (en) * | 2006-03-23 | 2012-03-14 | Absorber AB | Blood group antigens of different types for diagnostic and therapeutic applications |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
KR20090031897A (ko) * | 2006-06-12 | 2009-03-30 | 리셉터 바이오로직스 인크 | 전-세포 표면 수용체-특이적 치료제 |
TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
TW200902544A (en) | 2007-03-13 | 2009-01-16 | Hoffmann La Roche | Peptide-complement conjugates |
CN101679521B (zh) | 2007-03-22 | 2014-03-12 | 拜奥根Idec马萨诸塞公司 | 特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途 |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
US20130195881A1 (en) * | 2007-04-27 | 2013-08-01 | Sanjaya Singh | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
CL2008002092A1 (es) | 2007-07-20 | 2009-05-29 | Hoffmann La Roche | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. |
TWI464262B (zh) | 2007-09-26 | 2014-12-11 | 中外製藥股份有限公司 | 抗體固定區的變異 |
RU2510400C9 (ru) | 2007-09-26 | 2014-07-20 | Чугаи Сейяку Кабусики Кайся | Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr |
MX2010003757A (es) * | 2007-10-16 | 2010-04-27 | Symphogen As | Composiciones que comprenden multimeros optimizados de her1 y her3 y sus metodos de uso. |
RU2531521C2 (ru) | 2007-12-05 | 2014-10-20 | Чугаи Сейяку Кабусики Кайся | Антитело против nr10 и его применение |
HUE028962T2 (en) | 2008-03-13 | 2017-01-30 | Biotest Ag | Active ingredient for treating disease |
AU2009224690B2 (en) | 2008-03-13 | 2014-10-09 | Biotest Ag | Agent for treating disease |
CA2718184A1 (en) * | 2008-03-13 | 2009-10-08 | Biotest Ag | Agent for treating disease |
WO2009136298A2 (en) * | 2008-05-09 | 2009-11-12 | Recopharma Ab | Compositions and methods for inhibiting shiga toxin and shiga-like toxin |
WO2009136297A2 (en) * | 2008-05-09 | 2009-11-12 | Recopharma Ab | Compositions and methods for inhibiting toxin a from clostridium difficile |
JP2011520959A (ja) * | 2008-05-23 | 2011-07-21 | アルゴス・セラピューティクス・インコーポレーテッド | 新規可溶性cd83ポリペプチド、配合物および使用法 |
US20100021460A1 (en) * | 2008-07-15 | 2010-01-28 | Genentech, Inc. | Methods of Treating Autoimmune Diseases Using CD4 Antibodies |
JP5588983B2 (ja) | 2008-08-11 | 2014-09-10 | ウェルズ ファーゴ バンク ナショナル アソシエイション | マルチアームポリマーアルカノエートコンジュゲート |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
ES2528419T3 (es) * | 2008-09-29 | 2015-02-09 | Biotest Ag | Composición para el tratamiento de enfermedades |
ES2699434T3 (es) * | 2008-10-31 | 2019-02-11 | Wyeth Llc | Purificación de proteínas ácidas utilizando cromatografía de hidroxiapatita cerámica |
ES2602459T3 (es) | 2008-12-26 | 2017-02-21 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-CD4 |
EP3674317A1 (en) | 2009-03-19 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
US9340615B2 (en) | 2009-05-15 | 2016-05-17 | Chugai Seiyaku Kabushiki Kaisha | Anti-AXL antibody |
KR101778317B1 (ko) | 2009-08-13 | 2017-09-13 | 얀센 백신스 앤드 프리벤션 비.브이. | 사람 호흡기 세포융합 바이러스(rsv)에 대한 항체 및 이용 방법 |
WO2011035205A2 (en) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
WO2011133636A1 (en) * | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS |
BR112012031638B1 (pt) | 2010-07-09 | 2021-01-12 | Janssen Vaccines & Prevention B.V. | anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado |
UY33578A (es) * | 2010-08-31 | 2012-03-30 | Sanofi Sa | PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS |
EP2471543A1 (en) * | 2010-12-02 | 2012-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules |
EP2654771A1 (en) | 2010-12-21 | 2013-10-30 | Recopharma Ab | Tear substitutes |
US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
KR20130132880A (ko) | 2010-12-23 | 2013-12-05 | 사노피 | 간암의 치료에 사용하기 위한 robo1-fc 융합 단백질 |
PT2691417T (pt) | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
US20140088021A1 (en) | 2011-05-27 | 2014-03-27 | Nektar Therapeutics | Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds |
BR112014010008A2 (pt) | 2011-10-26 | 2018-09-04 | Novartis Ag | anticorpos monoclonais, seus usos e ácidos nucleicos |
JP6309518B2 (ja) | 2012-07-05 | 2018-04-11 | ジェネンテック, インコーポレイテッド | 発現及び分泌システム |
HUE056217T2 (hu) | 2012-07-13 | 2022-02-28 | Roche Glycart Ag | Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében |
EP2722341B1 (en) | 2012-10-22 | 2017-12-06 | Fountain Biopharma Inc. | Antibodies to interleukin-6 and uses thereof |
CA2899206C (en) | 2013-01-24 | 2019-07-09 | Transderm, Inc. | Compositions for transdermal delivery of mtor inhibitors |
WO2014135984A2 (en) | 2013-03-07 | 2014-09-12 | Recopharma Ab | Glycosylated mucin-immunoglobulin fusion protein coated device |
EP3000478A4 (en) * | 2013-05-23 | 2017-03-15 | IDAC Theranostics, Inc. | Therapeutic or prophylactic agent for immunodeficiency virus infection |
WO2015006519A1 (en) * | 2013-07-10 | 2015-01-15 | The United States Of America, As Represented By The Secretary, Departement Of Health &Human Services | Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans |
SG11201602261VA (en) | 2013-09-27 | 2016-04-28 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
EP3102233A4 (en) | 2014-02-05 | 2017-11-22 | Cedars-Sinai Medical Center | Methods and compositions for treating cancer and infectious diseases |
KR101892883B1 (ko) | 2015-02-27 | 2018-10-05 | 추가이 세이야쿠 가부시키가이샤 | Il-6 관련 질환 치료용 조성물 |
JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
CN106188292B (zh) * | 2015-05-05 | 2019-09-24 | 北京傲锐东源生物科技有限公司 | 抗cd4蛋白单克隆抗体及其用途 |
JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Fc領域含有ポリペプチドの精製を効率化するための方法 |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
CA3049402A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
EP3354278A1 (en) | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
WO2019160907A1 (en) * | 2018-02-14 | 2019-08-22 | University Of Virginia Patent Foundation | Regulating cd4+ t cells to treat clostridium difficile infection |
CN112119090B (zh) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
CN113244386A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
CN113248612A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗神经内分泌瘤中的用途 |
CN115197320A (zh) * | 2021-04-07 | 2022-10-18 | 中美冠科生物技术(太仓)有限公司 | 新型抗cd4抗体 |
TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向cd4之病毒載體之用途 |
WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023168426A1 (en) | 2022-03-03 | 2023-09-07 | Enosi Therapeutics Corporation | Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
US4975369A (en) * | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
DE3814887C1 (no) * | 1988-05-02 | 1989-09-21 | Medice Chem.-Pharm. Fabrik Puetter Gmbh & Co Kg, 5860 Iserlohn, De | |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
AU4964290A (en) * | 1989-01-18 | 1990-08-13 | President And Fellows Of Harvard College | Compositions and methods for treating or preventing aids, arc and hiv infection |
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
GB8912497D0 (en) * | 1989-05-31 | 1989-07-19 | Cobbold Stephen P | Monoclonal antibodies |
US5308839A (en) * | 1989-12-04 | 1994-05-03 | The Research Foundation Of State University Of New York | Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline |
CA2054983A1 (en) * | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
CA2111858A1 (en) * | 1991-07-15 | 1993-02-04 | James S. Crowe | Production of antibodies |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
EP1715045A3 (en) | 1991-07-25 | 2006-12-13 | Biogen Idec Inc. | Recombinant antibodies for human therapy |
MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
WO1994008619A1 (en) * | 1992-10-08 | 1994-04-28 | The Kennedy Institute Of Rheumatology | Treatment of autoimmune and inflammatory disorders |
US6024957A (en) * | 1993-06-02 | 2000-02-15 | Research Corporation Technologies, Inc. | Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same |
US5691183A (en) * | 1993-07-07 | 1997-11-25 | University Technology Corporation | CD4+ T-lymphoctye proteases and genes encoding said proteases |
-
1995
- 1995-09-06 US US08/523,894 patent/US6136310A/en not_active Expired - Lifetime
-
1996
- 1996-09-05 CA CA002231182A patent/CA2231182A1/en not_active Abandoned
- 1996-09-05 AP APAP/P/1998/001209A patent/AP1193A/en active
- 1996-09-05 NZ NZ316835A patent/NZ316835A/en not_active IP Right Cessation
- 1996-09-05 RO RO98-00703A patent/RO120198B1/ro unknown
- 1996-09-05 AT AT96929936T patent/ATE348113T1/de not_active IP Right Cessation
- 1996-09-05 JP JP51141197A patent/JP3619866B2/ja not_active Expired - Fee Related
- 1996-09-05 EP EP96929936A patent/EP0854885B1/en not_active Expired - Lifetime
- 1996-09-05 CN CNB961979437A patent/CN100391978C/zh not_active Expired - Fee Related
- 1996-09-05 BR BR9610404A patent/BR9610404A/pt not_active Application Discontinuation
- 1996-09-05 HU HU9802212A patent/HU221351B1/hu not_active IP Right Cessation
- 1996-09-05 RU RU98106117/13A patent/RU2232773C2/ru not_active IP Right Cessation
- 1996-09-05 AU AU69162/96A patent/AU717674B2/en not_active Ceased
- 1996-09-05 CZ CZ1998586A patent/CZ291036B6/cs not_active IP Right Cessation
- 1996-09-05 KR KR1019980701683A patent/KR100491222B1/ko not_active IP Right Cessation
- 1996-09-05 WO PCT/US1996/014324 patent/WO1997009351A1/en active IP Right Grant
- 1996-09-05 DE DE69636760T patent/DE69636760T2/de not_active Expired - Lifetime
- 1996-09-05 SK SK279-98A patent/SK27998A3/sk unknown
- 1996-09-05 IL IL12344796A patent/IL123447A0/xx unknown
-
1998
- 1998-03-03 NO NO19980915A patent/NO324497B1/no not_active IP Right Cessation
- 1998-03-04 MX MX9801732A patent/MX9801732A/es not_active IP Right Cessation
- 1998-03-06 OA OA9800029A patent/OA10671A/en unknown
- 1998-03-24 BG BG102343A patent/BG64651B1/bg unknown
-
1999
- 1999-05-03 HK HK99101977.7A patent/HK1016995A1/xx not_active IP Right Cessation
-
2000
- 2000-07-10 US US09/612,914 patent/US7452534B1/en not_active Expired - Fee Related
-
2002
- 2002-08-05 US US10/211,357 patent/US7338658B2/en not_active Expired - Fee Related
-
2008
- 2008-02-29 US US12/040,240 patent/US20090226430A1/en not_active Abandoned
- 2008-07-02 US US12/166,902 patent/US20090221036A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO980915D0 (no) | Rekombinante anti-CD4-antistoff egnet for human terapi | |
NO940219L (no) | Rekombinante antistoffer for human terapi | |
DE69617896D1 (de) | Humaner monoklonaler Antikörper gegen VEGF | |
FI973089A (fi) | Ihmisen interleukiini-1-reseptorin apuproteiini | |
EP1032421A4 (en) | NATURAL HUMAN MONOCLONAL ANTIBODIES | |
NO975621D0 (no) | Höyaffinitets-humane monoklonale antistoff spesifikke for RSV F-protein | |
NO991449L (no) | Antistoff mot human parathormon-relaterte peptider | |
EP0880597A4 (en) | THERAPEUTIC APPLICATIONS FOR MONOCLONAL ANTIBODY 5c8 ANTI-T-BAM (ANTI-CD40-L) | |
LV11630A (lv) | T sunu antigena receptora V apgabala pilna garuma olbaltumvielas | |
DE69528180T2 (de) | Modifiziertes molkeprotein | |
NO976058L (no) | Rekombinant mistellectin | |
GB9419021D0 (en) | Therapeutic protein | |
AU5021796A (en) | Recombinant human anti-lewis b antibodies | |
EP0977590A4 (en) | HUMAN MONOCLONAL ANTIBODIES | |
NO980375D0 (no) | Humant MP52 Arg protein | |
DE29512719U1 (de) | Monoklonale Antikörper gegen humanes Interleukin-10 | |
BR9709080A (pt) | Anticorpo monoclonal anti-MP52 humano | |
DE69434900D1 (de) | Menschliche chemokin-polypeptide | |
GB9508618D0 (en) | Therapeutic protein | |
SE9502576D0 (sv) | Therapeutic preparations for inhalation II | |
ZA925615B (en) | Recombinant antibodies for human therapy | |
DK0919617T3 (da) | Monoklonale antistoffer mod humant MP52 | |
GB9422293D0 (en) | Therapeutic protein | |
DE29504688U1 (de) | Therapeutisches Gerät | |
FI973162A0 (fi) | Liikalihavuutta vastustavia proteiineja |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |